US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Vigil Neuroscience, Inc. - Common Stock (NQ:VIGL)

8.050 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vigil Neuroscience, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today? ↗
Vigil Neuroscience stock is up with heavy trading of VIGL shares this morning on news of a $40 million investment from Sanofi. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! 
Via InvestorPlace
News headline image
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Vigil Neuroscience: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition ↗
Penny stocks are risky because of their insane volatility — but these have a chance to 10x your investments. 
Via InvestorPlace
News headline image
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition ↗
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. 
Via InvestorPlace
News headline image
Vigil Neuroscience to Present in Upcoming June Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024 ↗
VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023 ↗
VIGL stock results show that Vigil Neuroscience missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to... 
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Why Is Rare Neurological Disease Focused Vigil Neuroscience Stock Trading Lower Today? ↗
Vigil Neuroscience Inc (NASDAQ: VIGL) shares are down after the company released interim data from its Phase 2 IGNITE proof-of-concept clinical trial in patients with adult-onset leukoencephalopathy... 
Via Benzinga
News headline image
Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
US Stocks Edge Lower; Housing Starts Rise In October ↗
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite falling around 30 points on Friday. Following the market opening Friday, the Dow traded down 0.04% to 34,931.47 while the... 
Via Benzinga
Topics Stocks
News headline image
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >